With the public desperate for a solution to COVID-19, Moderna’s (MRNA) status has increased to such an extent that any good news coming out of its HQ ripples across the whole market. Moderna can take partial credit for the S&P 500’s uptick on Wednesday, following news of the positive development in its COVID-19 vaccine program.A study published in the New England Journal of Medicine showed that in the Phase 1 study of the biotech’s experimental vaccine mRNA-1273, all 45 patients produced antibodies to the coronavirus.Moreover, participants who received two 100-microgram doses of the vaccine (patients were given either 250, 100, …read more
Source:: Yahoo Finance
